on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Announces Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released its Form 8.3 disclosure under Rule 8.3 of the Irish Takeover Panel Act. This concerns its interest in Avadel Pharmaceuticals plc as of January 28, 2026. The form reveals that Vanguard holds a 5.99% stake in Avadel, with 5,833,370 ordinary shares valued at US$0.01 each.
The disclosure includes recent trade activities, detailing Vanguard's purchase of 2,236 shares at $21.54 each and sales of 4,284 and 31,704 shares at $21.54 and $21.55, respectively. No other cash-settled or stock-settled derivative transactions are noted. Additionally, Vanguard confirms that there are no indemnities or agreements that influence dealings with this stake.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news